Todd Hobbs, M.D. and CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), gave a clinical presentation entitled, “Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” at the Global NASH Congress.
During the presentation, Dr. Hobbs reviewed additional data from the positive AMBITION Phase 2a NASH clinical trial, and provided further details on three upcoming clinical studies of its lead drug candidate, rencofilstat:
- ASCEND-NASH: a 12-month Phase 2b clinical trial clinical trial in biopsy-proven F2/F3 NASH subjects.
- ALTITUDE-NASH: a four-month Phase 2 liver function trial in NASH F3 subjects.
- And HEPA-CRV431-209: a four-month Simon two-stage Phase 2a study in HCC (hepatocellular carcinoma).
The initiation of screening and enrollment in all three studies is currently expected to begin in the third quarter of 2022.
“The Hepion team has been hard at work over this past year preparing the clinical plans for these upcoming trials, and it is exciting to share details of these trials and look forward to when we soon begin to enroll subjects for all three,” Dr. Hobbs said in a statement.
Dr. Hobbs’ presentation is accessible here.
